ArticleBMC infectious diseases2025
Changes in the incidence of notifiable infectious diseases before, during, and after the COVID-19 pandemic in Mainland China.
Article in BMC infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Epidemiological Scenario of Human Leptospirosis in Brazil from 2015 to 2024.Epidemiologia (Basel, Switzerland) · 2026Article
- Spatiotemporal epidemiology of hepatitis B in Central China: urbanization drivers and implications for adult-targeted control strategies.BMC public health · 2026Article
- Forecasting monthly hepatitis B cases in China: a nationwide comparative study based on surveillance data.BMC public health · 2026Article
- Life-course restructuring of infectious mortality in China, 2004-2021: a national surveillance study.Frontiers in public health · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNonpharmaceutical interventions (NPIs) have positive effects on curbing the COVID-19 pandemic, but the spread of other infectious diseases remains unknown.
objectiveThis study aimed to explore the incidence of notifiable infectious diseases (NIDs) at different stages of the COVID-19 pandemic in Mainland China.
methodsWe extracted monthly cases of NIDs from the National Health Commission of the People's Republic of China from January 2020 to December 2023. The infections were classified as blood-borne/sexually transmitted diseases, intestinal diseases, zoonotic/insect-borne diseases and respiratory diseases. The Joinpoint regression model was used to quantify the temporal trends of NIDs by calculating annual percentage changes (APCs).
resultsThere is a negative correlation between the national ridership of urban rail transit and the national COVID-19 cases. During the two emergency response periods from January 2020 to March 2020 and November 2022 to January 2023, 1,760,990 cases and 804,266 cases of 22 types of NIDs were reported nationwide, which decreased by 25.54% and 74.64% respectively compared with the same period in 2019. For different NIDs, respiratory diseases had the greatest reduction (85.99%), followed by intestinal diseases (48.94%), zoonotic/insect-borne diseases (34.22%), and blood-borne/sexually transmitted diseases (33.30%).
conclusionsIt was found that strict containment measures decreased social mobility and reduced the number of most NID cases. However, with the weakening of NPIs, hand, foot, and mouth disease, epidemic hemorrhagic fever, influenza and pertussis cases notably increased. This study offers suggestions for preventing the spread of epidemics in extreme situations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.